A. Galetin

发表

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Hayley S. Brown, Kiyomi Ito, A. Galetin, 2005, British journal of clinical pharmacology.

CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions

Kiyomi Ito, A. Galetin, J. Houston, 2005, Journal of Pharmacology and Experimental Therapeutics.

Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2011, Drug Metabolism and Disposition.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

Leon Aarons, Nikolaos Tsamandouras, Aleksandra Galetin, 2014, Pharmaceutical Research.

Simultaneous Ivabradine Parent-Metabolite PBPK/PD Modelling Using a Bayesian Estimation Method

A. Galetin, K. Ogungbenro, M. Chenel, 2020, The AAPS Journal.

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates

Shiew-Mei Huang, Ping Zhao, Lei Zhang, 2018, Clinical pharmacology and therapeutics.

Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance

A. Galetin, A. Darwich, A. Rostami-Hodjegan, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Incorporation of lysosomal sequestration in the mechanistic model for prediction of tissue distribution of basic drugs

Aleksandra Galetin, A. Galetin, Frauke Assmus, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

A. Galetin, A. Rostami-Hodjegan, D. Scotcher, 2017, The Journal of Pharmacology and Experimental Therapeutics.

In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages.

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2017, Molecular pharmaceutics.

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

Malcolm Rowland, Michael Gertz, Aleksandra Galetin, 2012, Pharmaceutical Research.

Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data

Hugh A. Barton, Aleksandra Galetin, Yurong Lai, 2012, Drug Metabolism and Disposition.

Comparison of in‐vivo and in‐silico methods used for prediction of tissue: plasma partition coefficients in rat

Leon Aarons, Aleksandra Galetin, James Yates, 2012, The Journal of pharmacy and pharmacology.

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

Andrés Olivares-Morales, Leon Aarons, Aleksandra Galetin, 2013, Pharmaceutical Research.

Modelling atypical CYP3A4 kinetics: principles and pragmatism.

Aleksandra Galetin, J Brian Houston, A. Galetin, 2005, Archives of biochemistry and biophysics.

Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines

A. Galetin, J. Houston, D. Hallifax, 2008, Xenobiotica; the fate of foreign compounds in biological systems.

Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications

A. Galetin, J. Houston, A. Harrison, 2008, Drug Metabolism and Disposition.

CYP 3 A 4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions

Kiyomi Ito, A. Galetin, J. Houston, 2005 .

vitro clearance and permeability data

A. Galetin, J. Houston, Michael Gertz, 2010 .

P450 and UGT cofactors in alamethicin activated human liver microsomes

A. Galetin, J. Houston, P. Kilford, 2008 .

Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism

A. Galetin, J. Houston, B. Houston, 2006, Journal of Pharmacology and Experimental Therapeutics.

In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383

A. Galetin, J. Houston, Ayşe Ufuk, 2015, Pharmaceutical Research.

PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability

A. Galetin, K. Ogungbenro, Yueping Zhang, 2020, CPT: pharmacometrics & systems pharmacology.

A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance

A. Galetin, J. Houston, C. Säll, 2012, Drug Metabolism and Disposition.

Microsoft Word-83629875-file00.docx

A. Galetin, Kathryn E. Kenworthy, Karelle Ménochet, 2012 .

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches

Yuichi Sugiyama, Aleksandra Galetin, Jan Snoeys, 2018, Clinical pharmacology and therapeutics.

PBPK Simulation-Based Evaluation of Ganciclovir Crystalluria Risk Factors: Effect of Renal Impairment, Old Age, and Low Fluid Intake

A. Galetin, D. Scotcher, 2021, The AAPS Journal.

Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions

A. Galetin, M. Monshouwer, A. Rostami-Hodjegan, 2021, Clinical Pharmacokinetics.

Utilising magnetically isolated lysosomes for direct quantification of intralysosomal drug concentrations by LC-MS/MS analysis: An investigatory study with imipramine.

A. Galetin, D. Hallifax, A. Harrell, 2020, Journal of pharmaceutical sciences.

Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance

K. Hillgren, A. Galetin, J. Houston, 2018, Drug Metabolism and Disposition.

The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development

K. Giacomini, Shiew-Mei Huang, A. Galetin, 2018, Clinical pharmacology and therapeutics.

Novel Methodology for the Isolation of Lysosomes and Measurement of Intralysosomal Drug Accumulation

A. Galetin, D. Hallifax, A. Harrell, 2017 .

Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2014, Clinical pharmacology and therapeutics.

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP

Shiew-Mei Huang, Lei Zhang, A. Galetin, 2017, Clinical pharmacology and therapeutics.

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Yuichi Sugiyama, Hong Shen, Aleksandra Galetin, 2018, Clinical pharmacology and therapeutics.

Physiologically‐Based Pharmacokinetic Modelling of Creatinine‐Drug Interactions in the Chronic Kidney Disease Population

A. Galetin, P. Kalra, D. Scotcher, 2020, CPT: pharmacometrics & systems pharmacology.

ITC Commentary on the Prediction of Digoxin Clinical Drug–Drug Interactions from In Vitro Transporter Assays

A. Galetin, J. C. Kalvass, M. Zamek-Gliszczynski, 2014, Clinical pharmacology and therapeutics.

Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp Inhibition

D. Tweedie, X. Chu, Lei Zhang, 2018, Clinical pharmacology and therapeutics.

Microsoft Word-50999523-file00

A. Galetin, C. Säll, 2012 .

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Y. Sugiyama, K. Brouwer, X. Chu, 2020, Clinical pharmacology and therapeutics.

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population

L. Aarons, A. Galetin, S. Hall, 2017, Pharmacogenetics and genomics.

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

Ruedi Aebersold, Tom Dunkley, Aleksandra Galetin, 2014, Pharmaceutical Research.

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance

A. Galetin, A. Rostami-Hodjegan, D. Scotcher, 2017, Drug Metabolism and Disposition.

Application of a gut-liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil.

A. Galetin, N. Parrott, S. Fowler, 2022, Lab on a chip.

DMD050294 744..753

A. Galetin, J. Houston, Katherine L. Gill, 2013 .

A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents

A. Galetin, J. Leeder, S. Abdel‐Rahman, 2019, European Journal of Clinical Pharmacology.

When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations

A. Galetin, Kunal S. Taskar, Caroline Sychterz, 2021, Biopharmaceutics & drug disposition.

Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.

John D. Davis, A. Galetin, J. Houston, 2008, Current drug metabolism.

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

X. Chu, A. Galetin, M. Varma, 2022, Clinical pharmacology and therapeutics.

Pharmacokinetics and bioavailability of pentoxifylline in healthy volunteers-a comparative study of three oral formulations

A. Galetin, B. Miljković, B. Brzaković, 1997 .

Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

Y. Sugiyama, K. Brouwer, X. Chu, 2013, Clinical pharmacology and therapeutics.

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data

Aleksandra Galetin, J Brian Houston, Hayley S. Brown, 2006, Clinical pharmacokinetics.

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans

J B Houston, A. Galetin, J. Houston, 2005, Xenobiotica; the fate of foreign compounds in biological systems.

Impact of Hepatic CYP3A4 Ontogeny Functions on Drug–Drug Interaction Risk in Pediatric Physiologically‐Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study

A. Galetin, K. Ogungbenro, M. Chenel, 2021, Clinical Pharmacology & Therapeutics.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Martin Bergstrand, Xavier Pepin, Erik Sjögren, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

A. Galetin, J. Houston, N. Tsamandouras, 2014, Pharmaceutical Research.

Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling.

Aleksandra Galetin, A. Galetin, 2014, Methods in molecular biology.

Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Amin Rostami-Hodjegan, Aleksandra Galetin, Eleanor J Guest, 2009, British journal of clinical pharmacology.

Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions.

A. Galetin, J. Houston, Michael Gertz, 2010, Drug metabolism and pharmacokinetics.

Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4

A. Galetin, J. Houston, H. Pertinez, 2012, Drug Metabolism and Disposition.

Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes

Aleksandra Galetin, J Brian Houston, A. Galetin, 2012, Drug Metabolism and Disposition.

Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2008, Drug Metabolism and Disposition.

Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data

Aleksandra Galetin, A. Galetin, J. Houston, 2011, Drug Metabolism and Disposition.

Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data

A. Galetin, J. Houston, H. Cubitt, 2011, Drug Metabolism And Disposition.

IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4

A. Galetin, J. Houston, H. Burt, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

A. Galetin, J. Houston, S. Clarke, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Y. Sugiyama, K. Giacomini, S. Yee, 2018, Clinical pharmacology and therapeutics.

Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

Aleksandra Galetin, J Brian Houston, A. Galetin, 2014, Drug Metabolism and Disposition.

Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2013, Drug Metabolism and Disposition.

Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2010, Drug Metabolism and Disposition.

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

Aleksandra Galetin, A. Galetin, J. Houston, 2009, Drug Metabolism and Disposition.

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

A. Galetin, J. Houston, H. Cubitt, 2009, Pharmaceutical Research.

Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

A. Galetin, J. Houston, Michael Gertz, 2008, Expert opinion on drug metabolism & toxicology.

Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations

A. Galetin, J. Houston, Michael Gertz, 2008, Drug Metabolism and Disposition.

Multiple Inhibition Mechanisms and Prediction of Drug–Drug Interactions: Status of Metabolism and Transporter Models as Exemplified by Gemfibrozil–Drug Interactions

Aleksandra Galetin, A. Galetin, J. Houston, 2008, Pharmaceutical Research.

Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

Aleksandra Galetin, J Brian Houston, A. Galetin, 2007, Current drug metabolism.

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance

Aleksandra Galetin, Amin Rostami-Hodjegan, A. Galetin, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation

A. Galetin, M. Posada, A. Rostami-Hodjegan, 2016, The AAPS Journal.

Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.

A. Galetin, J. Houston, J. Miners, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors

A. Galetin, A. Rostami-Hodjegan, O. Hatley, 2017, Biopharmaceutics & drug disposition.

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Caroline A. Lee, J. Polli, J. Ware, 2015, Drug Metabolism and Disposition.

Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development

X. Chu, J. Polli, A. Galetin, 2014, Drug Metabolism and Disposition.

Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin

A. Galetin, J. Houston, Katherine L. Gill, 2012, Drug Metabolism and Disposition.

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.

A. Galetin, J. Houston, S. Clarke, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Quantifying gut wall metabolism: methodology matters

A. Galetin, A. Rostami-Hodjegan, O. Hatley, 2017, Biopharmaceutics & drug disposition.

Variation in Methodologies – Isolation of Intestinal Microsomes

A. Galetin, A. Rostami-Hodjegan, O. Hatley, 2016 .

ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision

K. Giacomini, X. Chu, Caroline A. Lee, 2018, Clinical pharmacology and therapeutics.

Noninvasive Preclinical and Clinical Imaging of Liver Transporter Function Relevant to Drug-Induced Liver Injury

J. G. Kenna, S. Sourbron, P. Hockings, 2018 .

Typical and Atypical Enzyme Kinetics

A. Galetin, J. Houston, Kathryn E. Kenworthy, 2003 .

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

A. Galetin, J. Houston, J. Miners, 2003, Drug metabolism and disposition: the biological fate of chemicals.

A. Galetin, K. Ogungbenro, M. Chenel, 2020, Clinical pharmacology and therapeutics.

In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

Shiew-Mei Huang, Lei Zhang, A. Galetin, 2017, Journal of pharmaceutical sciences.

PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION

Aleksandra Galetin, J Brian Houston, A. Galetin, 2006, Drug Metabolism and Disposition.

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions

L. Aarons, A. Galetin, A. Darwich, 2015, The AAPS Journal.

Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease

X. Chu, A. Galetin, K. Ogungbenro, 2022, Clinical pharmacology and therapy.

Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

Kayode Ogungbenro, Hong Shen, Shelby Barnett, 2018, Clinical pharmacology and therapeutics.

Quantitative Proteomic Map of Enzymes and Transporters in the Human Kidney: Stepping Closer to Mechanistic Kidney Models to Define Local Kinetics

A. Galetin, A. Rostami-Hodjegan, B. Achour, 2021, Clinical pharmacology and therapeutics.

Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation

Aleksandra Galetin, Amin Rostami-Hodjegan, A. Galetin, 2016, The AAPS Journal.

Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I

W. Humphreys, A. Galetin, K. Ogungbenro, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

Nikolaos Tsamandouras, Michael Gertz, Aleksandra Galetin, 2014, Pharmaceutical Research.

Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction.

Shiew-Mei Huang, Ping Zhao, Aleksandra Galetin, 2017, Journal of pharmaceutical sciences.

Meta-Analysis of Expression of Hepatic Organic Anion–Transporting Polypeptide (OATP) Transporters in Cellular Systems Relative to Human Liver Tissue

Aleksandra Galetin, Amin Rostami-Hodjegan, Brahim Achour, 2015, Drug Metabolism and Disposition.

Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model

Aleksandra Galetin, A. Galetin, J. Houston, 2012, Journal of Pharmacology and Experimental Therapeutics.

Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

A. Galetin, J. Houston, M. Rowland, 2013, Pharmaceutical Research.

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions

L. Aarons, A. Galetin, J. Houston, 2011, Drug Metabolism and Disposition.

UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES

Aleksandra Galetin, Kiyomi Ito, J Brian Houston, 2004, Drug Metabolism and Disposition.

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats

S. Sourbron, A. Galetin, K. Ogungbenro, 2021, Molecular pharmaceutics.

Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites

A. Galetin, J. Houston, J. Miners, 2008, Molecular Pharmacology.

Progress Towards Prediction of Human Pharmacokinetic Parameters from In Vitro Technologies

A. Galetin, J. Brian Houston, 2003, Drug metabolism reviews.

Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies.

A. Galetin, S. Krähenbühl, N. Parrott, 2022, Lab on a chip.

Microsoft Word-90450945-file00.docx

A. Galetin, A. Rostami-Hodjegan, B. Achour, 2014 .

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

Aleksandra Galetin, J Brian Houston, A. Galetin, 2011, Drug Metabolism and Disposition.

Microsoft Word-14766297-file00

A. Galetin, J. Houston, Y. Yabe, 2011 .

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions

Shiew-Mei Huang, Lei Zhang, A. Galetin, 2020, CPT: pharmacometrics & systems pharmacology.

ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans

M Jamei, M. Jamei, X. Chu, 2013, Clinical pharmacology and therapeutics.

Methods for predicting in vivo pharmacokinetics using data from in vitro assays.

Aleksandra Galetin, J Brian Houston, A. Galetin, 2008, Current drug metabolism.

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

L. Aarons, A. Galetin, K. Ogungbenro, 2021, Clinical pharmacology and therapeutics.

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

A. Galetin, S. Mukadam, Suzanne Tay, 2012, Pharmaceutical Research.

Drug–Drug Interaction Potential of Marketed Oncology Drugs: In Vitro Assessment of Time-Dependent Cytochrome P450 Inhibition, Reactive Metabolite Formation and Drug–Drug Interaction Prediction

A. Galetin, S. Mukadam, Suzanne Tay, 2012, Pharmaceutical Research.

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment

A. Galetin, A. Rostami-Hodjegan, S. P. F. Tan, 2022, Clinical pharmacology and therapeutics.

Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated indoxyl sulfate secretion in chronic kidney disease.

Aleksandra Galetin, Amin Rostami-Hodjegan, Rosalinde Masereeuw, 2019, Molecular pharmaceutics.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2015, Pharmaceutical Research.

Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.

A. Galetin, K. Ogungbenro, M. Chenel, 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In Vitro–In Vivo Extrapolation of OATP1B-Mediated Drug–Drug Interactions in Cynomolgus Monkey

A. D. Rodrigues, A. Galetin, J. Houston, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.

A. Galetin, J. Houston, R. Badhan, 2009, Journal of pharmaceutical sciences.

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions

L. Aarons, A. Galetin, A. Darwich, 2015, The AAPS Journal.

UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE : IMPACT OF VARIABILITY , CYP 3 A 5 , AND CYP 2 C 19 ON CYP 3 A 4 PROBE SUBSTRATES

Kiyomi Ito, A. Galetin, J. Houston, 2004 .

Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions.

Michael Gertz, Aleksandra Galetin, J Brian Houston, 2008, Expert opinion on drug metabolism & toxicology.

Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro–In Vivo Scaling of Hepatic Uptake Clearance

A. D. Rodrigues, A. David Rodrigues, Manthena V. S. Varma, 2018, Drug Metabolism and Disposition.

In vitro techniques to study drug-drug interactions of drug metabolism: Cytochrome P450

A. Galetin, J. Houston, 2010 .

In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383

A. Galetin, J. Houston, Ayşe Ufuk, 2015, Pharmaceutical Research.

Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data

A. Galetin, M. Posada, A. Rostami-Hodjegan, 2016, The AAPS Journal.

A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations

Shiew-Mei Huang, Lei Zhang, A. Galetin, 2020, CPT: pharmacometrics & systems pharmacology.

Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine

R. Aebersold, P. Cutler, A. Galetin, 2014, Pharmaceutical Research.

Typical and atypical enzyme kinetics, in Drug metabolism enzymes: Cytochrome P450 and other enzymes in drug discovery and development.

A. Galetin, B. Houston, K. Kenworthy, 2003 .

Predictive Utility of In Vitro Rifampin Induction Data Generated in Fresh and Cryopreserved Human Hepatocytes, Fa2N-4, and HepaRG Cells

A. Galetin, J. Houston, I. Templeton, 2011, Drug Metabolism and Disposition.

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters

A. Galetin, K. Ogungbenro, A. Rostami-Hodjegan, 2021, CPT: pharmacometrics & systems pharmacology.

The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data

L. Aarons, A. Galetin, A. Rostami-Hodjegan, 2013, Pharmaceutical Research.

Modelling and simulation of pharmacokinetic aspects of cytochrome P450-based metabolic drug-drug interactions

A. Galetin, N. Proctor, M. Dickins, 2007 .

Hepatic OATP-mediated clearance in the Beagle dog: assessing in vitro-in vivo relationships and applying cross species empirical scaling factors to improve prediction of human clearance

K. Hillgren, A. Galetin, J. Houston, 2018 .

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

J. G. Kenna, S. Sourbron, P. Hockings, 2023, Pharmaceutics.

Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.

A. Galetin, R. Badhan, J. Penny, 2009, Journal of pharmaceutical sciences.

microsomes: Comparison to liver and intestinal glucuronidation and impact of albumin

A. Galetin, J. Houston, Katherine L. Gill, 2012 .

Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development

X. Chu, J. Polli, A. Galetin, 2014, Drug Metabolism and Disposition.

Kinetic Characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs

A. Galetin, J. Houston, Y. Yabe, 2011, Drug Metabolism and Disposition.

Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data

A. Galetin, J. Houston, Michael Gertz, 2008, Drug Metabolism and Disposition.

Comparative Analysis of CYP3A Heteroactivation by Steroid Hormones and Flavonoids in Different in Vitro Systems and Potential in Vivo Implications

A. Galetin, A. Harrison, J. Henshall, 2008, Drug Metabolism and Disposition.

Title: Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I

A. Galetin, K. Ogungbenro, S. Barnett, 2018 .

Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data

A. Galetin, Katherine L. Gill, Michael Gertz, 2013, Drug Metabolism and Disposition.

Comparison of in‐vivo and in‐silico methods used for prediction of tissue: plasma partition coefficients in rat

L. Aarons, A. Galetin, J. Yates, 2012, The Journal of pharmacy and pharmacology.

Impact of hepatic CYP3A4 ontogeny functions on DDI risk in paediatric PBPK/PD modelling: critical literature review and ivabradine case study

A. Galetin, K. Ogungbenro, M. Chenel, 2020 .

In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages.

A. Galetin, J. Houston, Valeriu Damian, 2017, Molecular pharmaceutics.

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions

L. Aarons, A. Galetin, J. Houston, 2011, Drug Metabolism and Disposition.

Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design

Caroline A. Lee, J. Polli, J. Ware, 2015, Drug Metabolism and Disposition.

Supplementary Materials for: Model-based drug-drug interaction extrapolation strategy from adults to children –risdiplam in pediatric patients with spinal muscular atrophy

L. Aarons, A. Galetin, K. Ogungbenro, 2021 .